OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED) shares are down 19% after the company reported top-line results from the phase 2 PINNACLE clinical trial of tarextumab in previously untreated patients with extensive-stage small cell lung cancer. The combination of tarextumab plus chemotherapy results were undifferentiated from those of chemotherapy plus placebo, which means the trial did not meet its primary endpoint of progression-free survival or secondary endpoints of overall survival and biomarkers reflective of Notch pathway gene activation. Additionally, the company said it is discontinuing enrollment in the phase 1b clinical trial of brontictuzumab in combination with trifluridine/tipiracil in third-line colorectal cancer patients. The combination of brontictuzumab plus chemotherapy was not tolerable in this patient population. “Based on the events of today and last week, we will be undertaking a comprehensive portfolio prioritization review immediately,” OncoMed chairman and CEO Paul J. Hastings stated in the news release.
To view the full press release, visit: http://nnw.fm/xtX73
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics. OncoMed has internally discovered a deep pipeline of investigational drugs intended to address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. As part of a broad strategic alliance with Celgene Corporation, the company is developing demcizumab (anti-DLL4, OMP-21M18), navicixizumab (anti-DLL4/VEGF bispecific, OMP-305B83), rosmantuzumab (anti-RSPO3, OMP-131R10) and anti-TIGIT (OMP-313M32). OncoMed is independently developing several other therapeutic candidates while pursuing drug discovery research. For further information about OncoMed Pharmaceuticals, please see www.oncomed.com.
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer